Clinical and molecular characteristics of acute myeloid leukemia with MPL mutation

Figures & data

Table 1. Clinical characteristics of MPL-mutated MN patients.

	AML(n=19)	MDS(n=15)	MDS/MPN(n=6)	MPN(n=9)	P value
Subtype	AML-MRC(n=2)	MDS-MLD(n=4)	CMML(n=2)	ET(n=2)
	CML-BP(n=1)	MDS-RS(n=2)	MDS/MPN,u(n=4)	post-ET MF(n=1)
	therapy-related AML(n=1)	MDS-EB1(n=7)		PMF(n=6)
	De novo AML(n=15)	MDS-EB2(n=2)
Sex(n, %)					0.073
Male	10(52.6)	4(26.7)	5(83.3)	6(66.7)
Female	9(47.4)	11(73.3)	1(16.7)	3(33.3)
Age,years					0.615
Median	48	53	43	64
Range	19-84	31-81	32-80	26-80
WBC count,X109/L					0.106
Median	2.785	1.9	2.61	6.61
Range	0.71-68	0.84-4.96	1.07-25.69	0.89-15.81
Hemoglobin, g/dL					0.084
Median	8.35	7.3	9.6	10.5
Range	4.5-15.7	5.4-13.6	6.0-15.7	6.6-14.8
Platelet count,X109/L					0.001*
Median	43	46	174	791
Range	4-331	6-331	24-489	80-1166
Co-occurring mutation gene number,n					0.041*
Median	3	2	5	2
Range	0-8	1-7	3-8	0-5
MPL VAF,%					0.095
Median	47	19	14	38
Range	2-91	2.2-88	1.1-54	1.4-50
MPL mutation location,n(%)					0.015*
Extracellular domain	7(30.4)	3(18.8)	1(16.7)	2(18.2)
Transmembrane domain	1(4.3)	0(0)	1(16.7)	5(45.5)
Intracellular domain	15(65.2)	13(81.2)	4(66.6)	4(36.3)
Avaliable Karyotype,n(%)					0.467
Normal	7(70)	7(58.3)	2(40)	2(33.3)
Abnormal	3(30)	5(41.7)	3(60)	4(66.7)

Abbreviations: VAF refers to variant allele frequencies; * means the p value is less than 0.05.

Table 2. Clinical characteristics of MPL-mutated and MPL-wt AML patients.

Characteristic	MPL-mut AML (n=19)	MPL-wt AML (n=19)	P value
Sex (n,%)			Match
Male	10,52.6	11,57.9
Female	9,47.4	8,42.1
Age,years			Match
Median	48	43
Range	19–84	17–69
WBC count,X109/L			0.001*
Median	2.785	30.5
Range	0.71–68	1.52–315.73
Hemoglobin,g/dL			0.21
Median	8.35	8.3
Range	4.5–15.7	4.8–12.6
Platelet count,X109/L			0.9
Median	43	33
Range	4–331	5–302
ELN 2017 risk categary,n(%)			0.29
Favorable	3(15.8)	7(36.8)
Intermediate	9(47.4)	8(42.1)
Adverse	7(36.8)	4(21.1)
Induction therapy, n(%)			0.22
Standard chemotherapy regimen	11(57.89)	15(78.95)
Decitabine-based regimen	6(31.58)	4(21.05)
Supportive therapy	2(10.53)	0(0.00)
Response to induction therapy,n(%)			0.025*
CR	6(31.58)	13(68.42)
NR	13(68.42)	6(31.58)
Post-remission therapy,n(%)			0.157
Allo-HCT	10(52.63%)	14 (73.68)
not	9(47.37%)	5 (26.32)
Overall survival,months			0.236
Median	17.5	15
Range	2–37	5–26

Abbreviations:ELN refers to European LeukemiaNet; CR refers to complete remission;NR refers to not meet the criteria of CR ;* means the p value is less than 0.05.

Figure 1. The waterfall diagram of MPL-mutated AML patients.

Figure 2. MPL mutation profiles in AML patients.